PAE11 Antibody

Introduction to PDE11A Antibody

PDE11A antibody is a polyclonal reagent designed to target the human phosphodiesterase 11A (PDE11A) enzyme, which hydrolyzes cyclic nucleotides (cAMP and cGMP) to regulate intracellular signaling . This antibody is critical for studying PDE11A's role in endocrine disorders, such as Cushing disease and adrenocortical hyperplasia, and for investigating its expression in tissues like the brain, skeletal muscle, and kidneys .

Target Protein: PDE11A Enzyme

PDE11A is a dual-substrate phosphodiesterase with roles in steroidogenesis and neuronal signaling. Key properties include:

Sources:

Antibody Development and Validation

PDE11A antibodies are typically developed using recombinant protein immunogens and validated across applications:

• Immunogen: PDE11A fusion proteins or peptide fragments .

• Host Species: Rabbit-derived polyclonal antibodies dominate commercial offerings .

• Validation Methods:

  • Western Blot: Confirms specificity using tissues like rat testis .

  • Immunohistochemistry (IHC): Detects PDE11A in formalin-fixed paraffin-embedded tissues .

  • Knockout (KO) Controls: Critical for verifying antibody specificity .

Recent studies highlight that ~20% of commercial antibodies fail validation, underscoring the need for rigorous testing . PDE11A antibodies are often re-evaluated using KO cell lines to minimize off-target binding .

5.1. Disease Mechanisms

• PDE11A mutations are implicated in hormone dysregulation, contributing to adrenal tumors and hyperplasia .

• In preclinical models, PDE11A knockdown reduces steroidogenesis, suggesting therapeutic potential .

5.2. Pharmacological Studies

• PDE11A inhibitors are explored for treating endocrine disorders and cognitive deficits .

• Antibodies enable quantitative analysis of PDE11A expression in drug-response assays .

5.3. Technical Advances

• Recombinant PDE11A antibodies show superior performance in immunofluorescence compared to traditional monoclonals .

• Multiplexed assays using PDE11A antibodies help map protein interaction networks in signaling pathways .

6.2. Clinical Trials

While PDE11A antibodies are primarily research tools, mRNA therapies targeting PDE11A-related pathways are in early-phase trials for metabolic disorders .

Challenges and Future Directions

• Specificity Issues: Cross-reactivity with PDE subtypes (e.g., PDE2A, PDE5A) remains a concern .

• Biomarker Potential: PDE11A expression levels in serum are being explored for diagnostic applications .

• Therapeutic Development: Antibody-drug conjugates (ADCs) targeting PDE11A-expressing tumors are under preclinical evaluation .